Cost-effectiveness of a new autoantibody test added to Computed Tomography (CT) compared to CT surveillance alone in the diagnosis of lung cancer amongst patients with indeterminate pulmonary nodules
| Autor: | Andrew Sutton, Leon Jackson, Adam M. Hill, Geoffrey Hamilton-Fairley, Gurdeep S. Sagoo, Mike Fisher, Andrea Murray |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Lung Neoplasms
Cost effectiveness Economics Cost-Benefit Analysis Biopsy Cancer Treatment Social Sciences Lung and Intrathoracic Tumors Diagnostic Radiology 0302 clinical medicine Medicine and Health Sciences Medicine 030212 general & internal medicine Tomography health care economics and organizations Multidisciplinary medicine.diagnostic_test 030503 health policy & services Radiology and Imaging Cost-effectiveness analysis Markov Chains Surgical Oncology Oncology Disease Progression Multiple Pulmonary Nodules Radiology 0305 other medical science Indeterminate Research Article Clinical Oncology medicine.medical_specialty Imaging Techniques Science Cost-Effectiveness Analysis Surgical and Invasive Medical Procedures Neuroimaging Malignancy Research and Analysis Methods 03 medical and health sciences Malignant Tumors Diagnostic Medicine Blood test Humans Lung cancer Survival analysis Autoantibodies Probability business.industry Cancers and Neoplasms Biology and Life Sciences medicine.disease Survival Analysis Economic Analysis Quality-adjusted life year Computed Axial Tomography Non-Small Cell Lung Cancer Clinical Medicine business Tomography X-Ray Computed Neuroscience |
| Zdroj: | PLoS ONE PLoS ONE, Vol 15, Iss 9, p e0237492 (2020) |
| ISSN: | 1932-6203 |
| Popis: | Oncimmune's EarlyCDT®-Lung is a simple ELISA blood test that measures seven lung cancer specific autoantibodies and is used in the assessment of malignancy risk in patients with indeterminate pulmonary nodules (IPNs). The objective of this study was to examine the cost-effectiveness of EarlyCDT-Lung in the diagnosis of lung cancer amongst patients with IPNs in addition to CT surveillance, compared to CT surveillance alone which is the current recommendation by the British Thoracic Society guidelines. A model consisting of a combination of a decision tree and Markov model was developed using the outcome measure of the quality adjusted life year (QALY). A life-time time horizon was adopted. The model was parameterized using a range of secondary sources. At £70 per test, EarlyCDT-Lung and CT surveillance was found to be cost-effective compared to CT surveillance alone with an incremental cost-effectiveness ratio (ICER) of less than £2,500 depending on the test accuracy parameters used. It was also found that EarlyCDT-Lung can be priced up to £1,177 and still be cost-effective based on cost-effectiveness acceptance threshold of £20,000 / QALY. Further research to resolve parameter uncertainty, was not found to be of value. The results here demonstrate that at £70 per test the EarlyCDT-Lung will have a positive impact on patient outcomes and coupled with CT surveillance is a cost-effective approach to the management of patients with IPNs. The conclusions drawn from this analysis are robust to realistic variation in the parameters used in the model. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|